Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.

This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

We are led by an experienced business team that has built numerous successful biotech ventures, and raised hundreds of millions of dollars in venture capital. The scientific co-founders are world-renowned physician-scientists at Yale with extensive expertise in DNA repair, chemo/radiosensitizer development, translational research, and Phase I/II clinical trials in oncology. The co-founders have published their work in numerous high-impact journals, including Science, Nature, Nature Genetics, and Science Translational Medicine.

Our mission is to improve patient outcomes and save lives by developing better cancer therapeutics that specifically target the tumor and its underlying biology.

Cybrexa Leadership

Per Hellsund

Per Hellsund

Cybrexa President & CEO

Read bio ›

Ranjit Bindra, M.D., Ph.D.

Ranjit Bindra, M.D., Ph.D.

Cybrexa Chief Scientific Advisor

Read bio ›

Peter Glazer, M.D., Ph.D.

Peter Glazer, M.D., Ph.D.

Cybrexa Chief Medical Advisor

Read bio ›

Board Of Directors

Kevin Didden

Kevin Didden

Cybrexa Board Chairman

Read bio ›

Per Hellsund

Per Hellsund

Cybrexa President & CEO

Read bio ›

Kevin Rakin

Kevin Rakin

Cybrexa Board Member

Read bio ›

Contact Us

5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731